Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Nofima | OTHER |
| Norwegian University of Life Sciences | OTHER |
| Nortuna | UNKNOWN |
| Norilia |
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this project is to evaluate daily intake of eggshell membrane taken as supplement (capsule), will reduce markers of inflammation in older people.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention | Experimental | Participants will consume 2 capsules containing eggshell membrane(ESM) with breakfast every day in 4 weeks. |
|
| Placebo | Experimental | Participants will consume 2 capsules with no bioactive substance (placebo) with breakfast every day in 4 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Eggshell membrane (ESM) | Other | The intervention group will consume two capsules containing (in total) 500mg ESM with breakfast every day in 4 weeks. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in plasma levels of inflammatory markers | concentration of C-reactive protein (CRP) | Measured at baseline and after 4 weeks (end of study) |
| Change in plasma levels of inflammatory markers | concentration of TNFalpha | Measured at baseline and after 4 weeks (end of study) |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in body composition - measured by Bioimpedance (BIA) | fat free mass (% and kg), fatt mass (% and in kg) | Measured at baseline and after 4 weeks |
| Change in muscle strength | Measured by grip strength |
Not provided
Inclusion Criteria:
The study will include home-dwelling men and women ≥ 70 years. All subjects have to be in a good enough condition to meet up at the Department of Nutrition, University of Oslo at two occasions during the study period.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Stine M Ulven, PhD | University of Oslo | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Oslo | Oslo | Norway |
Not provided
| ID | Term |
|---|---|
| D007249 | Inflammation |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| Orkla | UNKNOWN |
| Danægg | UNKNOWN |
This study is a randomized double-blinded controlled trial and is considered as a pilot study.
Not provided
Not provided
One of the employees will distribute the capsules and know which of the group is placebo and intervention. Everyone else involved in the project will be blinded for this knowledge.
| Placebo | Other | The placebo group will consume two placebo capsules (Cellulose) with breakfast every day in 4 weeks |
|
| Measured at baseline and after 4 weeks |
| Changes in markers related to lipid metabolism | Blood concentrations of e.g. triglycerides, total-, LDL- and HDL- cholesterol, free fatty acids and lipoprotein subclasses | Measured at baseline and after 4 weeks |
| Peripheral blood mononuclear cell (PBMC) gene expression | mRNA levels of of genes involved in lipid metabolism and inflammation | Measured at baseline and after 4 weeks |
| Change in microbiota composition (optional) | Consenctration of faecal short-chain fatty acids | Measured at baseline and after 4 weeks |
| Change in microbiota composition (optional) | bacteria type and diversity | Measured at baseline and after 4 weeks |
| Changes in satiety hormones | e.g. concentration of serum ghrelin, amylin, leptin | Measured at baseline and after 4 weeks |
| Changes in metabolome plasma profile | concentration of amino acids in blood | Measured at baseline and after 4 weeks |
| Changes in metabolome plasma profile | concentration of low molecular molecules in blood | Measured at baseline and after 4 weeks |
| Changes in body weight | Weight (kg) measured by digital scale | Measured at baseline and after 4 weeks |
| Changes in body mass index (BMI) | Measured as body weight in kg/height in meter2 ( kg/m2) | Measured at baseline and after 4 weeks |
| Changes in physical performance | Short Physical Performance Battery (SPPB) test (includes balance test, chair test (sit to stand) and walk test) | Measured at baseline and after 4 weeks |